Form 4: Foghorn Therapeutics Executive Carlos Costa Executes Stock Options and Sells Shares Under 10b5-1 Plan

Carlos Costa, Chief People Officer of Foghorn Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Carlos Costa, Chief People Officer of Foghorn Therapeutics Inc., executed stock options and sold shares of common stock on September 20, 2024, and September 23, 2024.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on March 11, 2024.
• On September 20, 2024, Costa exercised options to acquire 35,756 shares at $3.72 per share and sold the same amount at a weighted average price of $10.04, with prices ranging from $10.00 to $10.22.
• On September 23, 2024, Costa exercised options to acquire 857 shares at $3.72 per share and sold the same amount at a price of $10.17.
• Following these transactions, Costa directly owns 0 shares of common stock.
• Costa continues to hold 40,646 and 39,789 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports transactions by an officer under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects. The use of a 10b5-1 trading plan indicates that the insider's sales were pre-planned and not based on current, non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The vesting schedule of the options, with 25% vesting after one year and the remainder vesting quarterly, is a common practice.
• The use of 10b5-1 trading plans is a widespread method for insiders to sell shares without raising concerns about insider trading.
• Comparable companies in the biotechnology sector, such as Amgen, Gilead Sciences, and Biogen, also have executives who utilize similar trading plans and stock option programs.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates